Raul Angel Garcia1,2, Mary C Benton1,2, John A Spertus3,4. 1. Saint Luke's Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO, 64111, USA. 2. University of Missouri-Kansas City, Kansas City, MO, USA. 3. Saint Luke's Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO, 64111, USA. spertusj@umkc.edu. 4. University of Missouri-Kansas City, Kansas City, MO, USA. spertusj@umkc.edu.
Abstract
PURPOSE OF REVIEW: As medicine strives to become more patient-centered, patient-reported outcomes (PROs) are often used to describe patients' symptoms, function, and quality of life. This review describes the key concepts of PROs specific to heart failure in clinical trials and their potential role in clinical practice. RECENT FINDINGS: As the Food and Drug Administration has increasingly emphasized how it values PROs as clinical outcome assessments, including its recent qualification of the Kansas City Cardiomyopathy Questionnaire (KCCQ), clinical trials have increasingly used them to evaluate novel therapies. This has been enhanced by an increasing understanding of how to interpret KCCQ scores. Its use in clinical practice, including the importance of providers sharing results with their patients, is just emerging. PROs provide unique insights into the benefits of treatment from patients' perspectives and while their role in clinical care is just beginning, they offer an important opportunity to improve the patient-centeredness of care.
PURPOSE OF REVIEW: As medicine strives to become more patient-centered, patient-reported outcomes (PROs) are often used to describe patients' symptoms, function, and quality of life. This review describes the key concepts of PROs specific to heart failure in clinical trials and their potential role in clinical practice. RECENT FINDINGS: As the Food and Drug Administration has increasingly emphasized how it values PROs as clinical outcome assessments, including its recent qualification of the Kansas City Cardiomyopathy Questionnaire (KCCQ), clinical trials have increasingly used them to evaluate novel therapies. This has been enhanced by an increasing understanding of how to interpret KCCQ scores. Its use in clinical practice, including the importance of providers sharing results with their patients, is just emerging. PROs provide unique insights into the benefits of treatment from patients' perspectives and while their role in clinical care is just beginning, they offer an important opportunity to improve the patient-centeredness of care.
Authors: Mitchell A Psotka; Robyn von Maltzahn; Milena Anatchkova; Irene Agodoa; Dina Chau; Fady I Malik; Donald L Patrick; John A Spertus; Ingela Wiklund; John R Teerlink Journal: JACC Heart Fail Date: 2016-07-06 Impact factor: 12.035
Authors: Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Anita A Kelkar; John Spertus; Peter Pang; Renee F Pierson; Robert J Cody; Ileana L Pina; Adrian Hernandez; Javed Butler Journal: JACC Heart Fail Date: 2016-02-10 Impact factor: 12.035
Authors: Stephen J Greene; Javed Butler; Nancy M Albert; Adam D DeVore; Puza P Sharma; Carol I Duffy; C Larry Hill; Kevin McCague; Xiaojuan Mi; J Herbert Patterson; John A Spertus; Laine Thomas; Fredonia B Williams; Adrian F Hernandez; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2018-07-24 Impact factor: 24.094
Authors: Yashashwi Pokharel; Yevgeniy Khariton; Yuanyuan Tang; Michael E Nassif; Paul S Chan; Suzanne V Arnold; Philip G Jones; John A Spertus Journal: JAMA Cardiol Date: 2017-12-01 Impact factor: 14.676